Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease by Hiley, Crispin T et al.
Challenges in molecular testing in non-small-cell lung cancer
patients with advanced disease
Hiley, C. T., Le Quesne, J., Santis, G., Sharpe, R., de Castro, D. G., Middleton, G., & Swanton, C. (2016).
Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet,
388(10048), 1002-11. DOI: 10.1016/S0140-6736(16)31340-X
Published in:
Lancet
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-
nd/4.0/ which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:06. Mar. 2017
	 1	
Challenges	in	molecular	testing	in	non-small	cell	lung	cancer	patients	with	advanced	1	
disease	2	
	3	
Crispin	T	Hiley	1,2,	John	Le	Quesne	3,	George	Santis	4,	Rowena	Sharpe	5,	David	Gonzalez	de	4	
Castro	6,	7,	Gary	Middleton	8,9	and	Charles	Swanton	1,10	*.	5	
	6	
1. Translational	Cancer	Therapeutics	Laboratory,	The	Francis	Crick	Institute,	London,	UK.	7	
2. Division	of	Cancer	Studies,	King's	College	London,	London,	UK.	8	
3. Department	of	Cancer	Studies,	University	of	Leicester,	Leicester,	UK.	9	
4. Department	of	Respiratory	Medicine	and	Allergy,	Kings	College	London,	UK.	10	
5. Cancer	Research	UK,	London,	UK.	11	
6. Centre	for	Molecular	Pathology,	Royal	Marsden	Hospital,	Sutton,	UK.		12	
7. School	of	Medicine,	Dentistry	and	Biomedical	Sciences,	Queens	University	Belfast,	UK.	13	
8. Institute	of	Immunology	and	Immunotherapy,	University	of	Birmingham,	Birmingham,	14	
UK.	15	
9. University	Hospital	Birmingham	NHS	Foundation	Trust,	Queen	Elizabeth	Hospital,	16	
Birmingham,	UK.	17	
10. CRUK	Lung	Cancer	Centre	of	Excellence,	UCL	Cancer	Institute,	London,	UK.	18	
	19	
*Correspondence	to:		Professor	Charles	Swanton.	The	Francis	Crick	Institute,	44	Lincolns	Inn	20	
Field.	WC2A	3LY.	charles.swanton@crick.ac.uk	21	
	22	
Summary:	23	
Lung	cancer	diagnostics	have	evolved	significantly	in	the	previous	decade.	The	challenge	of	24	
molecular	testing	to	identify	an	increasing	number	of	potentially	clinically	actionable	genetic	25	
variants,	 using	 smaller	 samples	 obtained	 via	 minimally	 invasive	 techniques,	 is	 significant.	26	
Tumour	 heterogeneity	 and	 cancer	 evolution	 in	 response	 to	 therapy	 means	 that	 repeat	27	
biopsies	or	circulating	biomarkers	are	likely	to	be	increasingly	useful	to	adapt	treatment	as	28	
resistance	develops.	We	highlight	 some	of	 the	 current	 challenges	 faced	 in	 clinical	 practice	29	
for	molecular	 testing	 of	 EGFR,	 ALK	 and	 new	 biomarkers	 such	 as	 PDL1.	 Implementation	 of	30	
next	generation	sequencing	(NGS)	platforms	for	molecular	diagnostics	in	non-small	cell	lung	31	
cancer	 is	 increasingly	 common	 allowing	 testing	 of	 multiple	 genetic	 variants	 from	 a	 single	32	
sample.	The	use	of	NGS	to	 recruit	 to	molecularly	stratified	clinical	 trials	 is	discussed	 in	 the	33	
context	of	the	UK	Stratified	Medicine	Programme	and	The	UK	National	Lung	Matrix	Trial.	34	
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	35	
Historical	overview	of	lung	cancer	diagnostics	36	
	37	
Lung	cancer	 is	 the	most	common	cause	of	mortality	 in	 the	UK,	accounting	 for	1	 in	5	of	all	38	
cancer	 deaths.(1)	 With	 the	 estimated	 global	 incidence	 in	 2012	 of	 1.83	 million	 cases	 it	 is	39	
important	 to	 reflect	 that	 a	 century	 ago,	 lung	 cancer	 diagnosis	 was	 a	 rare	 event.	 In	40	
comparison	to	the	current	epidemic,	 in	1912	Isaac	Adler’s	collection	of	374	case	reports	 in	41	
his	publication	Primary	Malignant	Growths	of	the	Lungs	and	Bronchi	represented	the	entire	42	
known	 global	 incidence	 at	 the	 time.	 A	 century	 later	 the	WHO	histological	 classification	 of	43	
malignant	epithelial	tumours	of	the	lung	recognizes	different	histologies	with	many	variants	44	
for	each	subtype	and	analyses	from	next	generation	sequencing	(NGS)	studies	have	divided	45	
this	disease	 into	molecular	subtypes	defined	by	distinct	somatic	alterations.(2-4)	This	review	46	
will	 focus	on	key	 challenges	 faced	 in	 current	 clinical	 practice	 for	molecular	 testing	 in	non-47	
small	 cell	 lung	 cancer	 (NSCLC).	 In	 broad	 terms	 the	 challenges	 are	 technical,	 logistical	 and	48	
related	to	tumour	biology	and	some	of	the	pertinent	issues	are	highlighted	(Figure	1).	49	
	50	
Identification	of	tumour	histology	51	
	52	
Historically	 the	 treatment	 focus	 for	 those	 with	 advanced	 NSCLC	 was	 selection	 of	 an	53	
appropriate	 cytotoxic	 chemotherapy	 regimen	 irrespective	 of	 histological	 subtype.	 Several	54	
large	 studies	 were	 published	 that	 showed	 the	 efficacy	 of	 various	 platinum	 doublet	55	
combinations	 were	 comparable	 but	 with	 differing	 drug	 specific	 toxicities.(5-7)	 However	56	
accurate	 classification	 of	 NSCLC	 subtype	 has	 become	 fundamental	 in	 the	management	 of	57	
advanced	 NSCLC	 following	 the	 results	 of	 phase	 III	 clinical	 trials	 showing	 improved	58	
progression	 free	 survival	 in	 EGFR	 mutation	 positive	 adenocarcinoma	 treated	 with	 EGFR	59	
tyrosine	kinase	inhibitors	(TKI),(8,9)	and	improved	overall	survival	with	pemetrexed	in	the	first	60	
line	and	maintenance	setting	for	those	with	non-squamous	histology.(10)(11)		61	
	62	
(12,13)The	 number	 of	 tumours	 that	 cannot	 be	 given	 an	 accurate	 histological	 diagnosis	 (i.e.	63	
adenocarcinoma	versus	squamous	cell	carcinoma)	has	reduced	significantly	with	the	use	of	64	
immunohistochemical	markers.	The	use	of	markers	for	p63,	p40	and	cytokeratin	CK	5/6	help	65	
to	 identify	 squamous	cell	 carcinomas,	while	 thyroid	 transcription	 factor	1	 (TTF1),	Napsin	A	66	
and	 CK7,	 as	 well	 as	 mucin	 stains,	 are	 indicative	 of	 adenocarcinomas.(14)	 However	67	
interpretation	of	immunohistochemistry	panels	still	requires	the	expertise	of	an	experienced	68	
histopathologist,	 as	 markers	 are	 not	 reliable	 in	 isolation.(15)	 TTF1	 for	 example,	 a	 marker	69	
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synonymous	with	adenocarcinoma,	 is	 expressed	 in	only	80-90%	of	 cases	 and	 is	 commonly	70	
expressed	in	neuroendocrine	tumours.(14,16)	Immunohistochemistry	can	only	be	meaningfully	71	
interpreted	in	a	detailed	morphological	context.	72	
	73	
Sampling	challenges	in	advanced	NSCLC	74	
	75	
The	analysis	of	 lung	cancer	 tissue	 is	particularly	challenging	as	primary	 lung	tumours	often	76	
show	 much	 lower	 tumour	 cellularity	 than	 other	 tumour	 types.	 Even	 with	 macroscopic	77	
selection	 of	 areas	 of	 frank	 carcinoma	 the	 tumour	 purity	 (the	 fraction	 of	 a	 given	 region	78	
containing	tumour	cells)	can	often	be	<20%	because	of	the	high	proportion	of	stromal	cells,	79	
lymphocytic	 infiltration	and	necrosis	(unpublished	observations	from	the	UK	Lung	TRACERx	80	
longitudinal	cohort	study).(17).	81	
	82	
This	 challenge	 is	 compounded	 by	 the	 nature	 of	 the	 specimen	 types	 routinely	 received	 by	83	
histopathology	and	molecular	diagnostics	laboratories.	Presentation	with	metastatic	disease	84	
is	 common	 and	 only	 a	 small	 proportion	 of	 patients	 with	 NSCLC	 undergo	 curative	 surgical	85	
resection.(18)	 The	 large	 tissue	 samples	 obtained	 via	 open	 thoracotomy	 (wedge	 resection,	86	
lobectomy,	pneumonectomy)	are	usually	of	sufficient	quantity	and	quality	 for	a	number	of	87	
histological	and	molecular	assays	if	handled	appropriately.	However	patients	with	advanced	88	
disease	are	predominately	diagnosed	with	CT	guided	percutaneous	or	US	guided	endoscopic	89	
biopsy	with	18	gauge	needles	or	with	fine	needle	aspiration.	These	patients	are	the	cohort	90	
where	molecular	diagnostics	are	most	 important	 for	determining	 the	standard	of	care	and	91	
enabling	participation	in	clinical	trials	yet	the	sample	quality	and	quantity	from	such	needle	92	
biopsies	is	the	most	limiting	for	histological	and	molecular	testing.		93	
	94	
Obtaining	adequate	tissue	for	diagnosis,	tissue	sub-typing,	molecular	profiling	and	treatment	95	
planning	are	therefore	key	to	patient	management.	The	target	tumour	 is	not	always	easily	96	
accessible	 in	 patients	 presenting	 with	 a	 probable	 lung	 cancer.	 The	 development	 of	97	
endobronchial	 ultrasound	 transbronchial	 needle	 aspiration	 (EBUS-TBNA)	 is	 proving	98	
increasingly	 important	 in	 the	 investigation	and	management	of	 thoracic	malignancies	as	 it	99	
offers	a	minimally	 invasive	approach	 to	 sampling	of	mediastinal	 lymph	nodes	and	masses.	100	
EBUS-TBNA	is	now	increasingly	embedded	in	routine	clinical	practice	with	wider	use	beyond	101	
high	 volume	 tertiary	 centres	 in	 the	UK	 and	USA.	 	 It	 is	 now	 generally	 accepted	 that	 EBUS-102	
TBNA	alone	or	in	combination	with	endoscopic	ultrasound	fine	needle	aspiration	(EUS-FNA)	103	
can	potentially	spare	surgical	mediastinoscopy	or	thoracotomy	in	the	staging	of	NSCLC.(19,20)	104	
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Importantly,	EBUS-TBNA	also	offers	 the	possibility	of	 combining	diagnosis	and	staging	as	a	105	
single	 procedure	 in	 patients	 with	 suspected	 lung	 cancer.	 In	 contrast	 to	 tissue	 biopsies	 or	106	
surgical	samples	that	allow	sub-typing	(adenocarcinoma	versus	squamous	cell	carcinoma)	on	107	
morphological	 criteria	 alone	 in	 the	majority	 of	 cases,	 evaluation	 of	 cytological	 specimens	108	
obtained	by	EBUS-TBNA	poses	additional	challenges	that	can	be	partly	overcome	with	wider	109	
use	of	immunohistochemistry.(21)		110	
	111	
Identifying	 driver	 mutations,	 such	 as	 EGFR	 and	 ALK,	 in	 these	 small	 samples	 is	 central	 to	112	
management	of	patients	with	advanced	disease.	Whether	molecular	analysis	is	successfully	113	
performed	depends	on	the	absolute	number	of	tumour	cells,	the	proportion	of	tumour	cells	114	
compared	 to	 total	 nucleated	 cells	 present	 and	 the	method	used	 for	molecular	 analysis.	 In	115	
case	of	EBUS-derived	samples,	 there	 is	evidence	to	conclude	that	simple	mutation	analysis	116	
(EGFR,	KRAS,	ALK)	can	be	successfully	performed	in	most	cases.(22-24)	The	use	of	multi-gene	117	
targeted	 NGS	 panels,	 using	 only	 nanograms	 of	 DNA,	 to	 sequence	 fine	 needle	 aspiration	118	
samples	is	achievable	and	is	becoming	more	commonly	used	in	clinical	practice.(25,26)	Whole	119	
exome	 sequencing	 (WES)	 and	 whole	 genome	 sequencing	 (WGS)	 analysis	 which	 require	120	
greater	 amounts	 of	 DNA,	micrograms	 in	 the	 case	 of	WGS,	 will	 be	more	 challenging	 from	121	
EBUS-TBNA	samples.		122	
	123	
	124	
Current	challenges	in	molecular	diagnostics	for	EGFR	mutation	analysis	in	clinical	practice	125	
	126	
The	 initial	 randomised	 phase	 II	 studies	 of	 gefitinib	 demonstrated	 clinical	 activity,(27,28)	 and	127	
phase	III	studies	although	negative	for	the	primary	outcome	measure,	suggested	a	benefit	in	128	
patients	 with	 adenocarcinoma,	 those	 of	 Asian	 origin	 and	 never	 smokers.(29,30)	 During	 this	129	
period	a	number	of	seminal	case	series	identified	EGFR	mutations	as	a	marker	of	sensitivity	130	
to	 EGFR	 TKIs,(31-33)	 and	 analysis	 of	 samples	 from	 these	 early	 trials	 supported	 this.(34)		131	
Subsequent	 phase	 III	 trials	 have	 incorporated	 EGFR	 mutation	 status	 and	 showed	 higher	132	
response	rates	and	progression	free	survival	 (PFS)	 in	patients	with	EGFR	activating	somatic	133	
mutations	treated	with	EGFR	TKIs	compared	to	when	treated	with	chemotherapy.(8,9,35)		134	
	135	
Development	of	diverse	mechanisms	of	resistance	and	selection	of	resistant	clones	in	136	
response	to	treatment	137	
The	common	EGFR	mutations	are	located	in	the	tyrosine	kinase	domain	(exon	18-21)	of	the	138	
	 5	
EGFR	gene,	with	detection	of	 L858R	and	deletions	 in	exon	19	 the	 clinical	priority	 as	 these	139	
determine	sensitivity	to	first	and	second	generation	TKIs.(36)	The	T790M	mutation	in	exon	20	140	
results	 in	 resistance	 to	 these	 therapies.(37)	 Sensitive	 assays	 suggest	 that	 tumour	 clones	141	
harbouring	the	T790M	mutation	are	often	detectable	prior	to	initiation	of	a	first	generation	142	
TKI	but	can	also	occur	by	genetic	evolution	in	T790M	mutation	negative	drug	tolerant	cells	in	143	
response	 to	 treatment.(38-40)	 Identification	 of	 this	 resistance	 mutation	 is	 more	 critical	144	
following	the	development	of	the	third	generation	EGFR	TKIs	active	against	T790M	mutation	145	
positive	 NSCLCs.(41,42)	 But	 whether	 these	 T790M	 resistant	 clones	 pre-exist	 or	 evolve	 in	146	
response	 to	 treatment	 may	 have	 clinical	 implications	 with	 differing	 sensitivities	 to	 third	147	
generation	TKIs.(40)	 The	 capacity	 for	 tumours	 to	evolve	 in	 response	 to	 first	 generation	TKIs	148	
results	 in	 an	additional	diverse	array	of	mechanisms	of	 resistance	 such	as	 amplification	of	149	
MET,	 selection	 for	 PIK3CA	 or	 BRAF	 mutations	 and	 transformation	 to	 a	 small	 cell	150	
phenotype.(43)	Clearly,	cancer	evolution	and	selection	of	resistant	subclones	is	not	restricted	151	
to	 first	 generation	 TKIs.	 This	 is	 highlighted	 by	 recent	 reports	 of	 the	 emergence	 of	 T790M	152	
mutation	 negative	 disease	 and	 the	 development	 of	 novel	 secondary	 EGFR	 resistance	153	
mutations	 (C797S)	 after	 treatment	 of	 T790M	 mutation	 positive	 patients	 with	 third	154	
generation	TKIs.(44,45)		155	
	156	
EGFR	mutation	testing	157	
The	 nature	 of	 EGFR	 sensitizing	mutations,	 being	 single	 nucleotide	 variants	 (SNV)	 or	 short	158	
deletions,	 lends	 themselves	 to	 molecular	 analysis	 of	 formalin	 fixed	 small	 samples	 which	159	
contain	 fragmented	 DNA.(46)	 There	 are	 a	 variety	 of	 methods	 to	 detect	 EGFR	 mutations	160	
including	 conventional	 Sanger	 sequencing,	 amplification	 refractory	 mutations	 systems	161	
(ARMS),	 restriction	 fragment	 length	polymorphisms	and	more	 recently	 as	part	of	 targeted	162	
NGS	 panels.(47,48)	 Reporting	 the	 limitations	 of	 an	 assay	 along	 with	 the	 result	 is	 critical	 for	163	
clinical	interpretation.	Bi-directional	Sanger	sequencing	without	a	mutation	enrichment	step	164	
has	a	lower	limit	of	detection	of	10-25%	of	total	DNA	meaning	that	the	use	of	samples	with	165	
low	 tumour	 cellularity	 can	 result	 in	 false	negative	mutation	 calls.	 Consequently	 the	use	of	166	
methods	 that	 can	 detect	 mutations	 in	 low	 tumour	 cellularity	 samples	 (<10%)	 is	167	
recommended.	Polymerase	chain	reaction	(PCR)	based	ultra	sensitive	and	NGS	methods	can	168	
generate	artefact	mutations	 leading	to	false	positive	results.	 	However	techniques,	such	as	169	
duplex	sequencing,	are	being	developed	to	overcome	the	inherent	error	rate	in	sequencing	170	
technologis(49)	 Formalin	 fixed	 samples	 are	 particularly	 prone	 to	 DNA	 damage	 and	 display	171	
disproportionate	 levels	of	C>T/G>A	changes	 in	the	1-10%	allele	frequency	range	which	can	172	
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result	 in	 false	positive	mutation	calls.(50)	Publication	of	 clinical	 trials	 results	on	 response	 to	173	
EGFR	 TKI	 in	 patients	 with	 real	 but	 less	 common	 EGFR	 mutations	 can	 help	 guide	 clinical	174	
decision-making.(51)	Detection	of	 EGFR	mutations	 as	part	 of	 a	WES	or	WGS	analysis	 allows	175	
multiple	 driver	 mutations	 to	 be	 queried	 simultaneously	 but	 the	 performance	 of	176	
bioinformatics	tools	to	call	mutations	from	NGS	data	varies.	 	Such	complexities	need	to	be	177	
considered	 as	 these	 technologies	 are	 increasingly	 adopted	 into	 mainstream	 clinical	178	
practice.(52-54)		179	
	180	
EGFR	mutations,	resistance	and	tumour	heterogeneity	181	
There	are	very	few	reports	of	discordance	of	EGFR	mutation	status	between	primary	disease	182	
and	metastatic	sites	and	these	may	be	due	to	technical	limitations	of	the	assays	used.(55)	Loss	183	
of	the	EGFR	mutation	was	not	a	mechanism	seen	in	seminal	studies.(43)	Studies	looking	at	the	184	
extent	 of	 intra	 tumour	 heterogeneity	 (ITH)	 in	 early	 lung	 cancer	 have	 shown	 EGFR	 to	 be	185	
exclusively	a	clonal	event	prevalent	throughout	the	tumour.	(56,57)	As	resistance	to	EGFR	TKI	is	186	
usually	 due	 to	 acquisition	 of	 secondary	mutations	 in	 EGFR	 or	 other	 driver	 genes	 the	 key	187	
challenge	 at	 the	 time	 of	 disease	 progression	 is	 to	 obtain	 a	 contemporaneous	 sample	 to	188	
inform	selection	of	second	line	therapy.	In	general	the	most	easily	accessible	lesion	is	used	189	
but	in	patients	with	a	poor	performance	status	this	may	not	be	a	trivial	task.	Due	to	tumour	190	
heterogeneity	it	is	possible	that	a	single	sample	may	be	insufficient	to	accurately	represent	191	
all	 the	 resistance	 mechanisms	 present	 or	 the	 breadth	 of	 subclonal	 driver	 events	 present	192	
across	multiple	disease	sites	following	progression	on	therapy.		193	
	194	
Current	challenges	in	molecular	diagnostics	for	ALK	testing	in	clinical	practice	195	
	196	
The	discovery	of	an	oncogenic	anaplastic	lymphoma	kinase	fusion	gene	(EML4-ALK)	in	2007	197	
identified	 another	 important	molecular	 cohort	 in	NSCLC.(58)	 Present	 in	 2-7%	of	NSCLC	ALK	198	
fusion	genes	are	restricted	to	adenocarcinoma	subtypes	and	are	more	common	in	younger	199	
patients	 and	 never-smokers.(59-61)	 Identification	 of	 this	 cohort	 is	 critical	 given	 the	 high	200	
response	 rates	 (57-74%)	 to	 ALK	 inhibition	 both	 as	 a	 first	 line	 therapy	 and	 after	 platinum-201	
based	 chemotherapy.(59,62,63)	 Subsequently	 other	 rare	 fusion	 genes	 have	 been	 identified	202	
involving	 ROS1,	 with	 similar	 exquisite	 sensitivity	 to	 kinase	 inhibition,(64)	 but	 also	 RET	 and	203	
NTRK	where	objective	response	rates	are	lower.(65,66)	204	
	205	
ALK	fusion	gene	detection	206	
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Testing	for	ALK	fusion	genes	brings	 its	own	particular	set	of	challenges.	ALK	 is	activated	by	207	
genomic	 rearrangement,	 leading	 to	 the	 expression	 of	 a	 chimeric	 protein	 containing	 the	208	
effector	part	of	the	ALK	tyrosine	kinase	fused	to	the	proximal	portion	of	another	protein.	In	209	
NSCLC	cancer	this	is	typically	a	balanced	translocation	with	the	ubiquitously	highly	expressed	210	
EML4	gene,(58)	although	rarely	other	partner	genes	may	be	 involved.(67,68)	Expression	of	the	211	
chimeric	protein	leads	to	upregulation	of	mitogenic	signalling	through	the	RAS/RAF	pathway	212	
and	 interruption	 of	 this	 pathway	 by	 ALK	 inhibitors	 causes	 cancer	 cell	 death	 and	 tumour	213	
regression.(62)	 ALK-mutated	 tumours	 often	 show	 unusual	 features	 on	 conventional	214	
microscopy,	such	as	cribriform	growth	patterns	and	‘signet	ring’	cells	with	large	vacuoles,(69)	215	
but	this	is	not	sufficiently	sensitive	or	specific	to	guide	treatment.	216	
	217	
The	 first	 widely	 adopted	 test	 for	 ALK-driven	 tumours	 was	 FISH	 (fluorescence	 in	 situ	218	
hybridisation),	approved	by	the	FDA	(US	Food	and	Drug	Administration)	in	2011.(70)	FISH	is	a	219	
technically	 demanding	 method,	 requiring	 specialised	 equipment	 and	 experienced	220	
practitioners.	Tissue	sections	or	cytology	specimens	are	subjected	to	a	protocol	 that	 labels	221	
either	side	of	the	ALK	breakpoint	locus	with	red	and	green	fluorescent	DNA	probes.	In	non-222	
transformed	cell	nuclei	the	coloured	dots	overlap	and	look	yellow,	while	in	translocated	cells	223	
isolated	 red	 and/or	 green	 signals	 are	 seen.	 For	 a	 reliable	 FISH	 assay	 the	 tissue	 must	 be	224	
adequate	 in	quantity	 and	quality.	 This	 can	be	more	 challenging	with	 small	 biopsy	 samples	225	
which	may	contain	few	cells	or	which	show	crushing	artefacts	that	can	impair	interpretation.		226	
	227	
In	 2015,	 an	 immunohistochemistry	 method	 was	 approved	 by	 the	 FDA.	 This	 approach	 is	228	
simpler	 in	 principle,	 using	 an	 antibody	 stain	 to	 detect	 abnormal	 ALK	 antigen	 expression.	229	
However,	 currently	 available	 antibodies	 do	 not	 give	 a	 strong	 signal	 and	 so	 an	 additional	230	
signal	amplification	steps	needs	to	be	employed.	This	places	the	test	beyond	the	capacity	of	231	
many	 small	 labs.	Nonetheless,	 the	modified	 test	 is	 cheaper	 than	 FISH,	 easier	 to	 interpret,	232	
and	 has	 the	 theoretical	 advantage	 of	 additionally	 detecting	 ALK	 expression	 following	 rare	233	
atypical	 rearrangements.	 After	 much	 investigation,	 recent	 studies	 suggest	234	
immunohistochemistry	can	be	an	adequate	stand-alone	diagnostic,	showing	extremely	high	235	
concordance	with	 FISH.(71)	 UK	 guidelines	 do	 not	 dictate	which	 test	 should	 be	 applied,	 and	236	
practices	 vary	 regionally,	 though	 FISH	 is	 still	 often	 regarded	 as	 the	 ‘gold	 standard’	 and	 is	237	
considered	 the	definitive	 test	 in	 the	US.(48)	As	our	understanding	of	 tumour	 taxonomy	and	238	
genotypes	advances,	 it	 seems	 inevitable	 that	 some	 form	of	NGS	platform	will	become	 the	239	
clinical	 standard	 for	 gene	 fusion	detection.(72)	 These	methods	have	 the	potential	 to	detect	240	
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ALK	(and	other)	rearrangements	in	either	a	targeted	panel	or	a	WES	or	WGS	approach.(73,74)	241	
(72)	242	
	243	
ALK	fusion	genes,	resistance	and	tumour	heterogeneity	244	
ALK	 fusion	 genes	 are	 considered	 to	 be	 clonal	 events	 with	 minimal	 discordance	 between	245	
primary	and	metastatic	lesions.(75)	They	were	considered	to	be	mutually	exclusive	with	EGFR	246	
mutations	 however	 recent	 reports	 suggests	 a	 small	minority	 of	 tumours	 can	 contain	 both	247	
ALK	 and	 EGFR	 positive	 clones.(76-78)	 The	 mechanisms	 of	 resistance	 seen	 following	 ALK	248	
inhibitor	therapy	again	demonstrate	tumour	evolution	with	secondary	mutations	in	ALK,	ALK	249	
copy	number	gain,	secondary	driver	mutations	in	other	genes	and	outgrowth	of	ALK	fusion	250	
gene	 negative	 clones	 reported.(79-82)	 Consequently	 contemporaneous	 sampling	 of	251	
progressive	disease,	by	needle	biopsy	or	analysis	of	cfDNA,	may	allow	real	time	analysis	of	252	
tumour	evolution	and	guide	therapy.		253	
	254	
Integration	of	multi-gene	NGS	testing	in	clinical	practice	255	
Routine	molecular	profiling	can	be	performed	at	scale	on	a	national	level.	Large	cooperative	256	
efforts	 in	 France	 and	 the	 USA	 used	 combinations	 of	 mutation	 specific	 PCRs,	 Sanger	257	
sequencing	and	FISH	analysis	to	assay	6-10	oncogenic	drivers	in	thousands	of	patients	with	258	
NSCLC	 and	 survival	 was	 improved	 for	 those	 treated	 with	 gene	 directed	 targeted	259	
therapies.(83,84)	 The	 use	 of	 next	 generation	 sequencing	 to	 simultaneously	 assay	 multiple	260	
oncogenic	drivers	is	attractive	because	less	DNA	is	required	compared	to	multiple	individual	261	
assays,	 there	 is	 a	 reduction	 in	 hands-on	 laboratory	 time,	 and	 complex	 FISH	 analysis	 for	262	
detection	of	fusion	genes	may	be	avoided.	A	recent	NGS	approach	used	an	amplicon	based	263	
approach	 to	 assay	 14	 genes	 used	 only	 50ng	 of	 DNA	 from	 FFPE	 samples.(85)	 This	 study	264	
provided	a	comprehensive	assessment	of	the	spectrum	of	mutations,	and	co-occurrence	of	265	
mutations,	 in	 adenocarcinoma	 and	 squamous	 cell	 carcinomas	with	 detection	 turn	 around	266	
times	of	less	than	two	weeks.	These	studies	and	those	of	The	Cancer	Genome	Atlas	highlight	267	
the	inter-patient	molecular	heterogeneity	of	NSCLC	(Figure	2).	Even	within	these	molecular	268	
cohorts	 intra-tumour	 heterogeneity	 could	 have	 significant	 effects	 on	 outcome	 as	269	
exemplified	 by	 a	 recent	 study	 showing	 that	 the	 clonality	 of	 FGFR	 amplification	 is	 an	270	
important	predictor	of	response	to	FGFR	inhibition.(86)	A	deeper	understanding	of	the	clonal	271	
or	 subclonal	 nature	 of	 driver	 events	 in	 NSCLC	 from	 sufficiently	 powered	 studies,	 is	 still	272	
awaited.	 Recruitment	 of	 patients	 with	 rare	 mutations	 to	 molecularly	 stratified	 trials	 is	273	
challenging,(87)	 and	 some	 advocate	 that	 modifications	 to	 existing	 paradigms	 in	 drug	274	
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development	 are	 required	 in	 the	 era	of	 genomic	 studies	 and	precision	medicine.(88)	Multi-275	
gene	or	WES	NGS	assays	are	likely	to	become	standard	practice	in	the	years	to	come	and	the	276	
ultimately	automated	provision	of	readable,	applicable	reports	of	complex	genomic	data	 is	277	
another	important	challenge.	278	
	279	
Current	challenges	in	molecular	diagnostics	for	PDL1	testing	in	clinical	practice	280	
	281	
Activation	 of	 inhibitory	 T	 cell	 checkpoint	 interactions	 in	 established	 tumours	 has	 been	282	
demonstrated	in	a	number	of	solid	tumours,	including	NSCLC,	and	this	suppresses	the	anti-283	
tumour	 immune	 response.(89,90)	 The	 aim	 of	 immunotherapy	 using	 antagonists	 of	 these	284	
inhibitory	T	cell	checkpoint	interactions	is	to	reactivate	anti-tumour	immunity.	PDL1	(B7-H1)	285	
is	a	 ligand	present	on	antigen	presenting	cells	 (APCs),	 including	 tumour	cells	 that	 interacts	286	
with	its	receptor	(PD-1)	on	T	cells	and	inhibits	T	cell	effector	functions.	PD-1	and	CD8	positive	287	
effector	T	cell	population	are	thought	to	be	the	tumour	reactive	subset	responsible	for	anti-288	
tumour	immunity.(91)	There	is	limited	knowledge	of	the	spatial	or	functional	heterogeneity	of	289	
tumour	 infiltrating	 lymphocyte	 (TIL)	 populations	 and	 the	 T	 cell	 checkpoint	 ligand-receptor	290	
interactions	within	solid	tumours.		291	
	292	
Recent	 randomised	 trials	 have	 shown	 activity	 of	 PD1	 and	 PDL1	 targeting	 antibodies	 in	293	
squamous	 and	 non-squamous	 NSCLC.(92-96)	 In	 most	 instances	 these	 agents	 have	 shown	294	
greater	activity	 in	patients	whose	tumour	expresses	PDL1	when	tested	using	 IHC.	However	295	
durable	 responses	are	seen	 in	patients	without	PDL1	expression.	This	 is	unsurprising	given	296	
the	technical	and	spatial	heterogeneity	of	PDL1	expression	in	NSCLC,	which	hampers	its	use	297	
as	a	predictive	biomarker.(97-99)	Studies	of	the	expression	of	PDL1	on	APCs	in	NSCLC	are	also	298	
contradictory	with	 respect	 to	 any	 correlation	with	 tumour	 infiltration	 of	 the	 effector	 CD8	299	
positive	T	cells.	(89,97,98)		300	
	301	
Regulation	 of	 PDL1	 expression	 is	 complex	 and	 controlled	 by	 both	 cell	 intrinsic	 and	 cell	302	
extrinsic	 factors.(100)	 This	 means	 that	 oncogene	 driven	 expression	 of	 PDL1	 can	 result	 in	303	
increased	 expression	 in	 the	 absence	 of	 significant	 underlying	 immunogenicity.(101)	 This	304	
underlying	 immunogenicity	 is	 thought	 to	 be	 a	 result	 of	 non-synonymous	 SNVs	 which	305	
generate	 neoantigens,	 mutated	 proteins,	 recognised	 by	 the	 TIL	 population.(102,103)	 The	306	
number	 of	 neoantigens	 harboured	 by	 a	 tumour	 could	 act	 as	 a	 potential	 biomarker	 for	307	
immunotherapy	 although	 there	 are	 technical	 challenges	 inherent	 with	 such	 complex	308	
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assessments.	Recent	data	also	suggest	that	neo-antigen	intratumour	heterogeneity	may	also	309	
be	associated	with	altered	checkpoint	inhibitor	response,	which	may	further	complicate	the	310	
use	of	such	assays	in	a	clinical	setting.(104)	311	
	312	
The	 advent	 of	 immunotherapy	 presents	 additional	 challenges	 for	molecular	 diagnostics	 in	313	
NSCLC.	Although	 IHC	 for	 PDL1	 can	be	performed	on	 the	 small	 samples	 often	used	 in	 lung	314	
cancer	diagnostics	there	is	the	risk	of	significant	sampling	bias	because	of	ITH.	The	dynamic	315	
nature	 of	 PDL1	 gene	 expression,(105,106)	 means	 a	 contemporaneous	 sample	 obtained	 by	316	
repeat	biopsy	may	be	 the	most	accurate	adding	additional	burden	and	expense	 to	current	317	
clinical	pathways.	Characterisation	of	neo-antigens	as	a	potential	biomarker	would	 require	318	
sufficient	 tumour	DNA	 for	WES	and	carries	 significant	expense	but	given	 the	cost	of	 these	319	
therapies	would	be	 justified	 if	 the	assay	were	sufficiently	predictive.	However	neo-antigen	320	
prediction	 algorithms	 are	 still	 in	 their	 infancy	 and	 evidence	 suggests	 that	 there	 are	 a	321	
proportion	of	patients	who	derive	no	clinical	benefit	from	checkpoint	inhibitor	therapy,	yet	322	
have	 tumours	with	a	neo-antigen	burden	above	 thresholds	 associated	with	 sensitivity	 and	323	
conversely	patients	with	low	neo-antigen	burden	who	benefit.	324	
	325	
Molecular	diagnostics	in	practice:	The	United	Kingdom	National	Lung	Matrix	Trial		326	
	327	
The	 Cancer	 Research	 UK	 Stratified	 Medicine	 Programme	 2	 (SMP2)	 screens	 samples	 from	328	
advanced	 NSCLC	 patients	 using	 NGS	 for	 known	 drivers	 that	 are	 considered	 clinically	329	
actionable.	The	aim	of	SMP2	is	to	establish	high-throughput	and	quality	genomic	screening	330	
at	a	national	 level	 in	the	UK.	Based	on	these	results,	patients	are	recruited	to	The	National	331	
Lung	 Matrix	 Trial	 (NLMT)	 (NCT02664935)	 a	 phase	 II	 umbrella	 study	 with	 both	 targeted	332	
therapy	and	immunotherapy	arms	for	patients	who	have	progressed	on	first	line	therapy.(107)	333	
In	 comparison,	 the	 Lung-MAP	 (NCT02154490)	 and	 SAFIR02	 Lung	 trial	 (NCT02117167)	 are	334	
umbrella	studies,	outside	of	the	UK,	for	patients	with	NSCLC	where	recruitment	is	preceded	335	
by	molecular	stratification	(Table	1).					336	
	337	
SMP2	 molecular	 pathology	 workflow	 utilises	 DNA	 from	 excess	 diagnostic	 biopsy	 tissue.	338	
Sections	 are	 sent	 from	 the	 referring	 clinical	 site	 and	 extracted	 by	 one	 of	 three	 central	339	
technology	hubs.	Samples	with	sufficient	amounts	of	DNA	(>50ng)	are	then	analysed	using	a	340	
custom	 28-gene	 targeted	 NGS	 panel.	 Having	 successfully	 screened	 over	 1000	 patients,	341	
patterns	 of	 mutation	 and	 prevalence	 are	 emerging	 across	 the	 genomic	 and	 clinical	 data.	342	
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Preliminary	 analysis	 indicates	 prevalence	 and	 distribution	 of	 SNVs	 consistent	 to	 published	343	
reports,	 including	 31.6%	 KRAS	 (of	 which	 19.7%	 show	 concomitant	 STK11	 mutation)	 and	344	
15.1%	EGFR	mutations	 in	patients	with	adenocarcinoma.	Over	the	past	year,	SMP2	has	 led	345	
to	 the	 recruitment	 of	 over	 60	 patients	 to	 the	 NLMT.	 A	 number	 of	 detailed	 audits	 have	346	
identified	 areas	 of	 improvement	 along	 the	 SMP2	 pathway;	 from	 patient	 recruitment,	 to	347	
sample	preparation	and	result	analysis.		348	
	349	
Whilst	 utilising	 excess	 DNA	 from	 the	 FFPE	 diagnostic	 biopsy	 has	 significant	 advantage	 for	350	
patients	 and	 clinical	 workload	 (as	 repeat	 biopsies	 are	 not	 required),	 only	 70%	 of	 samples	351	
sent	have	sufficient	DNA	to	enter	the	sequencing	pipeline.	This	is	in	part	due	to	FFPE	blocks	352	
being	 exhausted	 during	 the	 diagnostic	 process	 and	 a	 general	 reduction	 in	 the	 size	 of	353	
diagnostic	cores	over	time.	Consequently	the	minimum	number	of	sections	has	since	been	354	
increased	to	ensure	enough	DNA	is	obtained	up	front.	Some	recruiting	centres	quantify	DNA	355	
upfront,	which	 allows	 a	 faster	 feedback	 loop	 if	 insufficient	DNA	 is	 present.	 Sites	 can	 then	356	
obtain	 additional	 sample	 from	 the	 diagnostic	 block	 or	 through	 re-biopsy,	 if	 appropriate.	357	
However,	 differences	 in	 quantification	 methodology	 between	 local	 clinical	 centres	 and	358	
central	 technology	hubs	have	 led	 to	 samples	being	 sent	with	 less	 than	 the	 required	50ng,	359	
resulting	 some	 of	 these	 samples	 failing	 quality	 control	 metrics	 prior	 to	 sequencing.	 As	 a	360	
result	 changes	 in	 extraction	 methods	 and	 a	 standardized	 DNA	 concentration	 have	 been	361	
introduced.	362	
	363	
Unique	 to	NLMT	 is	 the	need	 to	determine	wild	 type	 status	of	 some	genes	 for	eligibility	 to	364	
certain	arms.	Patients	recruited	to	the	CDK4/6	inhibitor	palbociclib	arm	must	have	wildtype	365	
retinoblastoma	 1	 protein	 (RB1)	 in	 addition	 to	 deficiencies	 in	 cell	 cycle	 regulation.	 The	366	
determination	of	wildtype	status	requires	a	pre-sequencing	assessment	of	tumour	cellularity	367	
to	determine	appropriate	sequencing	depth.	However	there	can	be	significant	discordance	368	
between	 pathologist	 assessments	 of	 this.(108)	 Clearer	 guidance	 and	 online	 training	 should	369	
ensure	more	concordance	for	visual	assessment,	whilst	digital	solutions	may	provide	a	useful	370	
alternative.	A	number	of	computational	methods	exist	to	assess	tumour	purity	and	control	371	
for	both	stromal	cell	admixture	and	cancer	cell	ploidy	in	DNA	samples	from	next	generation	372	
sequencing	data.(109,110)			373	
	374	
Extremes	 of	 GC	 nucleotide	 content	 in	 certain	 genes	 (RB1	 and	 FGFR3)	 can	 result	 in	 an	375	
increased	number	of	 sequencing	 failures.	Additional	probe	 coverage	 in	 the	 targeted	panel	376	
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and	 correction	 for	 GC	 content	 in	 the	 data	 processing	 stage	will	 improve	 results	 for	 these	377	
difficult	to	sequence	regions.	Following	these	incremental	improvements	at	each	step	of	the	378	
molecular	pathology	workflow	we	have	 shown	 that	 the	number	of	 successfully	 sequenced	379	
samples	 that	would	 allow	 recruitment	 to	 the	NLMT	 increased	 and	 there	has	 also	been	 an	380	
increase	in	identification	of	potentially	actionable	mutations	that	would	permit	recruitment	381	
to	trials	other	than	the	NLMT.		382	
	383	
Future	solutions	384	
	385	
Understanding	tumour	heterogeneity	and	cancer	evolution	386	
At	present	the	technical	limitation	of	the	small,	and	potentially	low	tumour	cellularity	NSCLC	387	
samples,	 obtained	 from	 bronchoscopic	 and	 EBUS-TBNA	 samples	 means	 that	 the	 main	388	
challenge	 facing	 clinicians	 and	 pathologists	 is	 the	 need	 for	 ever	 greater	 amounts	 of	389	
information	from	diminishing	amounts	of	tissue.	It	is	therefore	imperative	that	the	quality	of	390	
diagnostic	 samples	 in	 the	 advanced	 NSCLC	 setting	 is	 of	 the	 highest	 order.	 How	 best	 to	391	
achieve	this	represents	a	challenge	for	health	service	providers	that	has	received	very	little	392	
attention	 thus	 far.	However	 the	 spectre	of	 ITH	and	 cancer	 evolution	means	 that	 sampling	393	
bias	and	the	presence	of	subclonal	driver	mutations,	causing	resistance	to	therapy,	are	likely	394	
to	 hinder	 clinical	 benefit	 of	 targeted	 therapeutics.(111,112)	 The	 UK	 Lung	 TRAcking	 Cancer	395	
Evolution	through	Therapy	trial	(NCT01888601)	is	currently	characterizing	the	extent	of	ITH	396	
in	 early	 surgically	 resected	 NSCLC	 and	 with	 longitudinal	 follow-up	 aims	 to	 determine	 the	397	
origins	of	tumour	subclones	contributing	to	relapse.(17)	There	is	evidence	from	other	tumour	398	
types	of	parallel	evolution,	acquisition	of	mutations	in	the	same	gene	or	signalling	pathway	399	
in	 distinct	 subclones,	 that	 may	 highlight	 an	 ‘evolutionary	 bottle	 neck’	 that	 could	 be	 an	400	
Achilles	 heel	 for	 subsequent	 cancer	 therapy.(113-115)	 Clonal	 analyses	 of	 a	 drug	 target	 and	401	
putative	resistance	events,	whether	they	are	present	in	all	tumor	cells	or	only	a	proportion,	402	
may	affect	 the	 response	 rate	and	progression	 free	 survival	 times	on	 targeted	 therapy	and	403	
this	 is	 being	 addressed	 in	 clinical	 trials	 including	 the	 DARWIN	 studies	 (NCT02314481,	404	
NCT02183883).	 Ultimately	 it	 may	 be	 that	 only	 through	 ‘warm’	 autopsy	 studies,	 where	405	
subclonal	 phylogenetic	 structures	 can	 be	 determined	 through	 sampling	 multiple	 sites	 of	406	
disease,	that	effective	strategies	to	forestall	cancer	evolution	can	be	elucidated.(116)		407	
	408	
Circulating	biomarkers	409	
The	 use	 of	 minimally	 invasive	 methods	 to	 detect	 mutations	 in	 circulating	 cell-free	 DNA	410	
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(cfDNA)	or	‘liquid	biopsies’	offers	the	potential	to	obtain	a	mutation	call	in	a	patient	where	411	
an	 invasive	 biopsy	may	 not	 be	 feasible.	 As	 tumour	 DNA	 from	 all	 sites	 of	 disease	 has	 the	412	
potential	 to	 enter	 the	 blood	 stream	 it	 may	 also	 be	 a	 better	 reflection	 of	 tumour	413	
heterogeneity	than	a	single	biopsy.(117,118)	The	use	of	cfDNA	to	detect	resistance	mechanisms	414	
in	 patients	 treated	 with	 EGFR	 TKIs,	 often	 prior	 to	 radiographic	 progression,	 has	 been	415	
demonstrated.(45,119,120)	This	has	resulted	in	the	development	and	approval	of	a	commercially	416	
available	 assay	 of	 cfDNA	 in	 plasma	 that	 can	 detect	 a	 spectrum	 of	 EGFR	 mutations	 in	417	
including	the	T790M	mutation	amenable	to	targeting	with	third	generation	TKIs.		418	
	419	
Circulating	 tumour	 cells	 (CTCs)	 are	 tumour	 cells	 that	 can	 be	 isolated	 from	 the	 peripheral	420	
blood	and	are	a	complementary	circulating	biomarker	 to	cfDNA.	 	CTCs	are	a	versatile	 tool,	421	
cell	enumeration	can	be	prognostic,	immunohistochemistry	permits	further	characterization,	422	
single	cell	DNA	or	RNA	sequencing	 is	possible	and	 tumour	xenografts	 can	be	generated	 to	423	
assess	 drug	 response.(121-125)	 However	 at	 present	 the	 complexity	 of	 separation	 from	 other	424	
cells	in	the	peripheral	circulation	and	the	need	to	process	samples	promptly	for	functional	or	425	
genomic	 studies	 results	 in	 greater	 expense	 in	 comparison	 to	 cfDNA	 analysis.	 Circulating	426	
biomarkers	 will	 make	 a	 significant	 impact	 on	 cancer	management	 in	 the	 near	 future	 and	427	
readers	 are	 directed	 to	 more	 extensive	 reviews	 focusing	 on	 CTCs,	 cfDNA	 and	 other	428	
circulating	nucleotides.(121,126-129)	429	
	430	
Conclusion	431	
The	challenges	for	molecular	diagnostics	in	NSCLC	are	largely	paralleled	across	other	tumour	432	
types.	Resolving	these	issues	will	require	technology	improvements	in	addition	to	a	greater	433	
understanding	 of	 tumour	 biology.	 The	 logistical	 challenges	 of	 implementing	 the	 next	434	
generation	of	molecular	diagnostics	 into	clinical	practice	are	equally	as	challenging.	Clinical	435	
governance,	 information	 technology	 infrastructure,	 data	 storage,	 pathways	 in	 sample	436	
processing	 and	 training	 and	 professional	 developments	 in	 histopathology,	 respiratory	437	
medicine	and	oncology	will	need	investment.	With	these	great	challenges	comes	significant	438	
opportunity	 to	 improve	the	success	 rate	and	efficiency	of	drug	development	 in	NSCLC	and	439	
ultimately	patient	outcomes.	440	
	441	
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Figure	1:	Summary	of	the	key	technical,	logistical	and	biological	challenges	for	molecular	testing	
in	NSCLC.	
	
	
Figure	2:	Pie	charts	showing	the	approximate	distribution	of	clinically	relevant	driver	mutations	
identified	 to	 date	 in	 individuals	 with	 NSCLC.	 The	 genomic	 variants	 shown	 are	 potentially	
clinically	 actionable	 variants.(130)	 The	proportions	presented	are	based	on	estimates	 from	 the	
referenced	 studies	 and	 data	 sources,	 including	 the	 Stratified	 Medicine	 Programme	 2	
(unpublished	data).(2,3,85,131)	These	studies	examine	SNVs,	copy	number	variants	and	gene	fusion	
products	using	different	sequencing	technologies	and	sequencing	depth	resulting	in	inter-study	
variation	 and	 therefore	 the	 data	 is	 presented	 in	 aggregate	 form	 and	 represents	 an	
approximation.	CCGA	(Cell	cycle	genomic	aberration);	loss	of	Cyclin-Dependent	Kinase	Inhibitor	
2A	 or	 amplification	 of	 Cyclin-Dependent	 Kinase	 4	 or	 Cyclin	 D1	 in	 the	 presence	 of	 wildtype	
RB1.(107)	 EGFR,	 Epidermal	 growth	 factor	 receptor;	 LKB1,	 Liver	 Kinase	 B1;	 ALK,	 anaplastic	
lymphoma	 kinase;	 MET,	 MET	 Proto-Oncogene,	 Receptor	 Tyrosine	 Kinase;	 FGFR,	 fibroblastic	
growth	 factor	 receptor;	 NRAS,	 neuroblastoma	 RAS	 viral	 (v-ras)	 oncogene	 homolog;	 DDR2	
Discoidin	 Domain	 Receptor	 Tyrosine	 Kinase	 2;	 AKT1,	 v-akt	 murine	 thymoma	 viral	 oncogene	
homolog	 1;	 PTEN,	 Phosphatase	 And	 Tensin	 Homolog;	 PIK3CA,	 phosphoinositide-3-kinase,	
catalytic,	 α	 polypeptide;	 BRAF,	 v-raf	 murine	 sarcoma	 viral	 oncogene	 homolog	 B1;	 ERBB2,	
human	epidermal	growth	factor	receptor	2;	KRAS,	v-Ki-ras2	Kirsten	rat	sarcoma	viral	oncogene	
homolog;	TP53,	Tumor	Protein	P53.	
	
	
Table	1:	Comparison	of	molecularly	stratified	umbrella	studies	in	NSCLC.	PFS	=	progression	free	
survival,	 ORR	 =	 objective	 response	 rate,	 R	 =	 randomised,	 NR	 =	 non-randomised,	 SCC	 =	
squamous	cell	carcinoma,	CCGA	=	cell	cycle	genomic	aberration.	
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Technical	
• Novel	biopsy	techniques	(eg	EBUS)	
genera=ng	smaller	samples	with	
diminished	tumour	cellularity	
• Mul=ple	tests	with	the	poten=al	for	
discordant	results	(eg	IHC	vs	FISH	for	
ALK	muta=on)	
• Technology-speciﬁc	failures	due	to	
diﬀerences	in	sensi=vity/known	
artefacts	(eg	sequencing	through	
repeats/high	GC	areas)	
• Quality	assurance	of	genomic	
medicine	despite	across	mul=ple	
plaQorms	and	data	analysis	algorithms	
Logis=cal	
• Turnaround	=me	of	assays	in	a	
clinically	relevant	=meframe	
• Desirability	of	centralised	vs	
distributed/local	tes=ng	approaches	
• Educa=on	and	training	of	laboratory	
and	clinical	staﬀ	n	new	technologies	
• Dis=lla=on	of	high	volume	data	into	
useful	standardised	reports	usable	by	
clinicicans	
• Computa=onal	and	data	storage	
capacity	for	NGS	within	a	healthcare	
system	
Tumour	Biology	
• Diversity	of	molecular	subgroups	
within	NSCLC	
•  inter-pa=ent	heterogeneity	
•  Intra-tumour	heterogeneity		
• sampling	bias	
• diﬀeren=al	responses	
• Cancer	evolu=on	and	resistance	in	
response	to	treatments	
• need	for	longitudinal	sampling	
• Evolving	treatment	paradigms	
•  immuno-oncolog	&	new	biomarkers	
(eg	PDL-1,	neoan=gen	load)	
•  Increasing	complexity	of	detectable	
genomic	changes	in	cancer	
• eg	epigene=c	changes	&	non-coding	
variants	
Adenocarcinoma  
35%
KRAS
No variant
EGFR
LKB1
ALK
Cell cycle variant
MET
DDR2
Other
BRAF
FGFR
ERBB2
75%
mutant wildtype
TP53 status
Squamous Cell Carcinoma
No variant
Cell cycle 
variant
FGFR
PIK3CA
PTEN
KRAS
MET
DDR2
Other
57% 43%
mutant wildtype
			
	
	
Study	 Line		 Phase		 POM	 Molecular	subgroups	 Location	
National	
Lung	Matrix	
Trial	
2nd	or	later		 NR	Phase	II	 PFS	
ORR	
AKT,	PIK3CA/PTEN,	TSC,	
LKB1,	KRAS,	NRAS,	NF1,	MET,	
ROS1,	EGFR	(T790M),	CCGA,	
immunotherapy		
UK	
SAFIR_02	
Lung	Study	
1st	line	
maintenance	
R	Phase	II	 PFS		 mTOR,	AKT,	FGFR,	HER2,	
EGFR,	MEK,	immunotherapy	
France	
Lung	MAP	 2nd	or	later	
(SCC)	
NR	Phase	II		 PFS		
ORR	
PIK3CA,	FGFR,	CCGA,	
immunotherapy	
USA	
Darwin	I/II	 1st	or	later	 NR	Phase	II	 PFS	 EGFR,	HER2,	ALK,	RET,	BRAF,	
immunotherapy	
UK				
